Cytomx Therapeutics vs Proqr Therapeutics
Cytomx Therapeutics is the larger business, with $76.2m of revenue in fiscal 2025 against $18.0m for Proqr Therapeutics (4.2 times as much). Proqr Therapeutics grew faster (-12.1% against -44.8%). Cytomx Therapeutics kept more of each dollar of sales as profit: a net margin of -22.8% against -265.2%. Cytomx Therapeutics carries less debt relative to equity (0.0% against 9.9%).
| Latest fiscal year | Cytomx TherapeuticsCTMX, 2025 | Proqr TherapeuticsPRQR, 2025 |
|---|---|---|
| Revenue | $76.2m | $18.0m |
| Revenue growth | -44.8% | -12.1% |
| Net income | −$17.4m | −$47.7m |
| Operating margin | -29.3% | -273.1% |
| Net margin | -22.8% | -265.2% |
| Return on equity | -35.2% | -63.8% |
| Free cash flow | −$75.8m | −$60.8m |
| Cash | $12.7m | $108m |
| Total debt | $0 | $5.7m |
| Debt to equity | 0.0% | 9.9% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 69 | — |
| Market value | $372m | $144m |
| Price vs our value range | — | — |
| Moat score | 9 (Weak) | — |
| Insider trades, 12 months | 0 buys, 7 sales | 5 buys, 0 sales |